Traws Pharma appoints John Leaman as independent director, formalizes CEO and CFO titles

Traws Pharma, Inc.

John Leaman, MD appointed independent director effective Oct 1, 2025; joins Audit Committee.
Interim titles removed: Iain Dukes now CEO, Charles Parker now CFO of Traws Pharma.
Dr. Leaman brings experience as CFO of Cellarity, Impel Pharma, Selecta Biosciences.
Company progressing Phase 2 studies for lead candidate ratutrelvir (COVID-19 treatment).
CFO Charles Parker compensated via Stout at $500/hr, up to $50k/month for services.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.